Evidence map›Paper›PMID 41870384›Full record

Observational studyAmerican journal of hematology2026

The Longitudinal Effect of APOL1 Risk Alleles on Sickle Cell Anemia-Associated Kidney Function.

Sara R Rashkin, Guolian Kang, Clifford M Takemoto, Mitchell J Weiss, Kenneth I Ataga, Santosh L Saraf, Jeffrey Lebensburger, Rima S Zahr

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02098863 (Sickle Cell Clinical Research and Intervention Program), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02098863 recruitingnot on this map

Sickle Cell Clinical Research and Intervention Program

Typeobservational_patient_registrySponsorSt. Jude Children's Research HospitalRan2014 to 2044Enrolled10,000ConditionsSickle Cell Disease
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sara R RashkinDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0001-5542-6891
Guolian KangDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-6102-0115
Clifford M TakemotoDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-2832-6884
Mitchell J WeissDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0003-2460-3036
Kenneth I AtagaCenter for Sickle Cell Disease, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.ORCID 0000-0002-4501-9982
Santosh L SarafDivision of Hematology and Oncology, University of Illinois Chicago, Chicago, Illinois, USA.ORCID 0000-0002-8584-4194
Jeffrey LebensburgerDivision of Pediatric Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0001-5011-1022
Rima S ZahrDivision of Pediatric Nephrology and Hypertension, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0002-3631-7195

Funding

Genetic modifiers of Sickle Cell Kidney DiseaseK23HL157554 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Rima Zahr · 2022 to 2026
$849k
Mentoring & Patient-Oriented Research in Sickle Cell-Related Kidney DiseaseK24HL177273 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Santosh Saraf · 2025 to 2026
$274k
NHLBI NIH HHS K23 HL157554NHLBI NIH HHS K24 HL177273NIH HHS K23HL157554
6 · The paper itself

Abstract

Progressive kidney injury is a major cause of morbidity and mortality in sickle cell anemia (SCA). The high risk APOL1 G1/G2 variants contribute to the development of kidney disease in individuals of African ancestry, including those with SCA. However, few studies have evaluated the longitudinal effect of APOL1 variants in children and young adults. We analyzed the association of APOL1 risk variants with kidney function in 494 individuals aged 1 to 25 in the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study (clinicaltrials.gov #NCT02098863). Before age 10, APOL1 G1/G2 alleles were not associated with time to CKD (hazard ratio [HR] = 1.87; p = 0.14), hyperfiltration (HR = 0.96; p = 0.88), or continuous eGFR (β = -0.0090; p = 0.71). However, after age 10, APOL1 G1/G2 variants were associated with higher baseline eGFR (β

Indexed as

AllelesAnemia, Sickle CellApolipoprotein L1AdolescentAdultChildChild, PreschoolFemaleGlomerular Filtration RateHumansInfantKidneyLongitudinal StudiesMaleRisk FactorsYoung AdultAPOL1 protein, humanApolipoprotein L1APOL1kidney functionsickle cell anemia

Identifiers

PMID41870384
PMCPMC13139885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.